In reply to @arcinstitute

With plans to make Germinal open source, the team is lowering the barrier for antibody discovery and opening new doors for both basic research and potential therapies. Learn more in the full preprint: https://www.biorxiv.org/content/10.1101/2025.09.19.677421v1.full.pdf